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Therapeutic  approach  of  stem  cell  carrying  retroviral  replicating
vectors in human glioma model.  
Akihito  Inagaki1,  Masamichi  Takahashi2,  Shuichi  Kamijima2,  Kei
Hiraoka2,  Quincy  Tam2,  Emmanuelle  Faure-Kumar2,  Janet  Treger2,
Brooke Bogan2,  Katrin Hacke2,  Sara Collins1,  Douglas Jolly3,  Noriyuki
Kasahara1
1 University of California, San Francisco
2 University of California, Los Angeles
3 Tocagen, Inc.
Toca 511, an improved retroviral replicating vectors (RRVs) expressing
a codon-optimized cytosine deaminase, has shown highly promising
evidence of therapeutic benefit in preclinical and clinical studies for
gene therapy of glioma.  In the present study, we engineered human
mesenchymal stem cells (MSC) as tumor-homing cellular carriers that
produce and release RRV, and evaluated the effect of this mode of
virus delivery on the time course of intratumoral RRV dissemination.
Human MSC isolates  were  engineered  to  produce  RRV  (MSC-RRV).
Cytotoxicity assays confirmed efficient prodrug activator function in
U-87 glioma cells transduced with vectors produced from MSC-RRV.
To  evaluate  intratumoral  migration  activity  and  tumor-homing
migration activity in vivo, individual MSC isolates were injected either
directly into human glioma xenografts, or into the contralateral brain
hemisphere.  MSC-RRV  isolates  showing  the  highest  levels  of
intratumoral  migration activity  were selected, and the efficiency of
intratumoral dissemination and tumoricidal activity achieved by these
isolates was compared against injection of RRV virus preparations in
subcutaneous glioma models.  Compared to virus injection, MSC-RRV
achieved 1.6x-higher levels of tumor transduction (p<0.05), and 2x-
reduced tumor growth (p=0.018) at earlier time points.  In short-term
survival  studies  using  lower  doses  of  MSC-RRV cells  vs.  RRV virus
injected 14 days post-establishment of intracranial U-87 gliomas, a
small but statistically significant prolongation of median survival was
seen with intracranial tumors treated with MSC-RRV as compared to
RRV (26 vs. 20 days, p<0.05) after only a single cycle of 5-FC prodrug.
Thus, MSC can be employed as mobile tumor-homing RRV-producer
cells, which release RRV as they migrate to tumor foci  in vivo and
actively  penetrate  into  individual  tumor  masses,  resulting  in  more
rapid tumor transduction and earlier therapeutic efficacy, which may
be advantageous particularly for multi-focal and metastatic disease.
This  study  was  funded by  the  California  Institute  for  Regenerative
Medicine (TR2-01791).
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